Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Xumin Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4262-3463; OpenAlex author ID A5033715748. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2019: 2 papers · 2020: 6 papers · 2021: 5 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 4 papers · 2026: 1 paper

Papers 19

  1. Long-term outcomes of upfront pancreatectomy with venous resection for pancreatic cancer: a single-center, retrospective analysis. Co-author DOI 10.1097/js9.0000000000003617↗
  2. Comparison of Radical Antegrade Modular Pancreatosplenectomy Versus Standard Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Mat… Co-author DOI 10.1002/wjs.12630↗
  3. Exploring the biological mechanism and clinical value of perineural invasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217515↗
  4. Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT… Co-author DOI 10.1038/s41416-025-03061-x↗
  5. Editorial Expression of Concern to: The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-025-07740-8↗
  6. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Co-author DOI 10.1186/s12943-022-01636-3↗
  7. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST… Co-author DOI 10.1016/j.pan.2021.05.300↗
  8. Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Co-author DOI 10.1038/s41388-021-01741-5↗
  9. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Co-author DOI 10.1186/s12943-021-01333-7↗
  10. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  11. Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. Co-author DOI 10.3389/fcell.2021.714718↗
  12. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Co-author DOI 10.1002/ijc.32827↗
  13. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Co-author DOI 10.1016/j.canlet.2020.08.001↗
  14. The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-020-2475-3↗
  15. Optimization of internal reference genes for qPCR in human pancreatic cancer research. Co-author DOI 10.21037/tcr.2020.02.48↗
  16. LncRNA KCNK15-AS1 inhibits pancreatic cancer progression by promoting the expression of its binding protein ACTR3B Co-author DOI 10.21203/rs.3.rs-55282/v1↗
  17. [Comparison of radical antegrade modular pancreatosplenectomy with conventional distal pancreatectomy for pancreatic adenocarcinoma of the body and tail]. First author DOI 10.3760/cma.j.cn112139-20200413-00301↗
  18. YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. Co-author DOI 10.1016/j.canlet.2019.07.019↗
  19. YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways. Co-author DOI 10.1038/s41416-019-0604-5↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 14 shared papers, 2019–2026 · strength 1.93
  2. Qun Chen · 13 shared papers, 2019–2025 · strength 1.76
  3. Lingdong Meng · 12 shared papers, 2019–2025 · strength 1.54
  4. Peng Shen · 11 shared papers, 2019–2025 · strength 1.43
  5. Wanli Ge · 11 shared papers, 2019–2025 · strength 1.40
  6. Yi Miao · 12 shared papers, 2019–2021 · strength 1.31
  7. Zipeng Lu · 8 shared papers, 2020–2026 · strength 1.20
  8. Hao Yuan · 8 shared papers, 2019–2025 · strength 0.98
  9. Yi Miao · 4 shared papers, 2022–2025 · strength 0.82
  10. Pengfei Wu · 3 shared papers, 2025–2026 · strength 0.70
  11. Kuirong Jiang · 4 shared papers, 2020–2025 · strength 0.65
  12. Guodong Shi · 5 shared papers, 2020–2025 · strength 0.65
  13. Baobao Cai · 4 shared papers, 2021–2025 · strength 0.60
  14. Junli Wu · 3 shared papers, 2020–2026 · strength 0.56
  15. Jingjing Zhang · 5 shared papers, 2019–2021 · strength 0.53
  16. Lei Chen · 4 shared papers, 2019–2025 · strength 0.52
  17. Taoyue Yang · 4 shared papers, 2021–2022 · strength 0.48
  18. Kai Zhang · 2 shared papers, 2025–2026 · strength 0.47
  19. Jie Yin · 2 shared papers, 2025–2026 · strength 0.47
  20. Pengfei Wu · 4 shared papers, 2020–2021 · strength 0.43
  21. Pengfei Wu · 3 shared papers, 2020–2022 · strength 0.36
  22. Wentao Gao · 2 shared papers, 2020–2026 · strength 0.34
  23. Min Tu · 2 shared papers, 2020–2026 · strength 0.34
  24. Jishu Wei · 2 shared papers, 2020–2025 · strength 0.32
  25. Guangfu Wang · 2 shared papers, 2021 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.